ArticleMaterials today. Bio2026
An immunomodulatory bioactive glass orchestrates early bone healing via coordinated macrophage polarization and osteogenesis-osteolysis balance.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective repair of large bone defects remains a major challenge in regenerative medicine. Conventional strategies often emphasize enhancing osteogenesis, while the role of the early immune microenvironment remains insufficiently addressed. Bone regeneration is not merely a structural filling process but a complex physiological program orchestrated by the immune system, requiring a dynamic balance between osteogenesis and osteolysis. Here, we propose an immune-instructive strategy aimed at modulating the early immune response to establish a favorable microenvironment for efficient bone regeneration. Based on this concept, a pH-neutral bioactive glass functionalized with Arginine-Glycine-Aspartic Acid-Serine (RGDS) peptides, designated as NBG@RGDS, was designed and fabricated to achieve synchronized and multi-targeted regulation of the osteoimmune microenvironment. This system concurrently orchestrates three pivotal stages in osteoimmunology including polarizing macrophages toward a pro-repair M2 phenotype, inhibiting excessive osteoclastogenesis and osteoclast activity, and promoting the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Transcriptomic analysis suggested the potential mechanisms through which NBG@RGDS regulates macrophages. In a rat femoral condyle defect model, NBG@RGDS optimized the early immune landscape, effectively attenuated inflammation, and markedly accelerated early-stage new bone formation. This study demonstrates that modulating the initial immune crosstalk represents a more fundamental and efficient strategy for bone regeneration than merely stimulating osteogenesis. It provides a novel perspective for the development of next-generation immunomodulatory bone repair materials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.